Quantification And Application Of The Placental Epigenetic Signature Of The Rassf1a Gene In Maternal Plasma

Fuxi Zhao,Jian Wang,Runhua Liu,Jing Yang,Ke Cui,Yongming Wu,Juncheng Guo,Yaqin Mu,Xiying Wang
DOI: https://doi.org/10.1002/pd.2546
2010-01-01
Prenatal Diagnosis
Abstract:Objectives The aims of the detection of hypermethylated RASSF1A gene in maternal plasma from all three trimesters of pregnancy were to show its feature of cell-free fetal DNA and to make up deficients of genetic markers. This study also aimed at investigating of its application value in pre-eclampsia compared with third trimester.Methods Eighty pregnant women (7-41 gestational weeks) including normal pregnant women (60 cases) and pre-eclamptic pregnant women (20 cases) were selected as study groups and 20 normal non-pregnant women were selected as control group. Free DNA of plasma samples was extracted, and RASSF1A levels before and after double-methylation-sensitive restriction enzyme digestion of Hin P 1 I and Hha1 were determined to measure total and fetal cell-free DNA, respectively. beta-Actin gene was detected as a control to confirm complete enzyme digestion.Results The median concentrations of hypermethylated RASSF1A gene were 46 copies/mL in first trimester, 96 copies/mL in second trimester, 527 copies/mL in third trimester and 1947 copies/mL in pre-eclampsia. There was positive correlation between fetal-derived hypermethylated RASSF1A levels and the severity of pre-eclampsia.Conclusion Hypermethylated RASSF1A gene may be considered as an epigenetic marker to detect the fetal DNA in maternal plasma and expands the clinical application of non-invasive prenatal diagnosis. Copyright (C) 2010 John Wiley & Sons, Ltd.
What problem does this paper attempt to address?